194 results about "Kidney disorder" patented technology

The disclosure provides compositions and methods for the detection of renal disease and periodontal disease in mammals.

The invention relates to a flavonoid active fraction of an Abelmoschi corolla, a preparation method and an application thereof, and belongs to the field of traditional Chinese pharmaceutics. A high-purity Abelmoschi corolla flavonoid active fraction is prepared, which is found to have better therapeutic activity for kidney disease, and especially have a significant therapeutic effect for diabetic kidney disease and lupus nephritis, or contrast-induced kidney injury and eye diseases. Meanwhile, the Abelmoschi corolla flavonoid active fraction described in the invention also has good safety.

The embodiment of the invention discloses a model optimization method based on transfer learning. The method comprises the following steps: acquiring to-be-migrated learning data, wherein the to-be-migrated learning data comprises source domain data associated with pathological characteristics of kidney diseases; semantic alignment processing is carried out on the source domain data and target domain data, the target domain data is kidney disease pathology data, and a semantic alignment result is obtained; determining a feature distribution result corresponding to the target domain data, and determining a migration weight corresponding to the source domain data based on the feature distribution result and the semantic alignment result; and optimizing the target domain model based on the migration weight, the source domain data and the target domain data to obtain an optimized target domain model. According to the embodiment of the invention, the accuracy and robustness of the target domain model in a kidney disease pathological diagnosis task and the generalization ability of different data distributions can be remarkably improved.

The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and / or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).

The present disclosure provides methods of treating a subject having a kidney disease or preventing a subject from developing into a kidney disease by administering an angiopoietin-like 3 (ANGPTL3) inhibitor and a solute carrier family 5 member 2 (SLC5A2) inhibitor, and methods of identifying a subject having an increased risk of developing into a kidney disease.

The invention relates to the technical field of gene engineering, in particular to a method for constructing a pou3f3 mutant model, the pou3f3 mutant model and application. The method comprises the following steps: designing an sgRNA target nucleotide sequence of a targeted pou3f3 gene, shearing the pou3f3 gene in an animal model through a CRISPR / Cas9 gene editing technology so as to realize pou3f3 gene mutation, and finally carrying out passage screening to obtain a double homozygous mutant of pou3f3a mutation and pou3f3b mutation, a pou3f3a homozygous mutant or a pou3f3b homozygous mutant model. According to the method, synchronous knockout of the two homologous genes pou3f3a and pou3f3b can be effectively realized, a reliable experimental model is provided for researching gene functions and related diseases, and the model can also be used for researching hereditary kidney diseases.

The invention relates to the field of medical treatment, in particular to application, a model and a method of a protein fragment of urine regulatory protein in preparation of a kidney disease early detection product, and the amino acid sequence of the protein fragment of the urine regulatory protein is any shown in SEQ ID NO.1-8. The model constructed according to the protein fragment of the urine regulatory protein can be used as a non-invasive tool for early detection and monitoring of kidney diseases, and by analyzing the unique mode of the protein fragment existing in a urine sample, the model which indicates renal insufficiency, renal function and renal function can be identified before the traditional clinical biomarker is abnormal. Therefore, intervention can be carried out earlier.

The invention discloses a preparation method of a myeloid cell triggered receptor 2 protein polyclonal antibody and application of the polyclonal antibody in inhibition of renal fibrosis, and belongs to the technical field of medical molecular biology. The myeloid cell triggered receptor 2 protein is expressed by macrophages, and verification in the mechanism aspect is carried out on the protein; meanwhile, the polyclonal antibody is synthesized according to the polypeptide of the protein, then the effect of the antibody on treating the renal fibrosis is verified again, and a more targeted and personalized method is provided for diagnosis, treatment and management of the renal fibrosis and related kidney diseases.

The invention relates to the technical field of preparation of organoids, and discloses a method for regulating and controlling human induced pluripotent stem cells to differentiate into kidney organoids, which comprises the following steps: resuspending a cell cluster formed by human induced pluripotent stem cells by using a basic differentiation culture solution containing a GSK-3beta inhibitor, inoculating the cell cluster into an ultralow adsorption cell culture plate, and starting to culture, marking the time as the 0th hour of differentiation; and after culturing for 70-76 hours, replacing the basic differentiation culture solution containing the GSK-3beta inhibitor with a basic differentiation culture solution containing a Knockout TM serum substitute (KSR), and continuing to carry out differentiation culture. By adopting the method disclosed by the invention, the human induced pluripotent stem cells can be efficiently, quickly, simply, conveniently and stably subjected to directional induced differentiation into kidney organs containing podocytes, renal tubules and other structures, and the time for constructing a kidney in-vitro model can be shortened, so that the research on kidney diseases, kidney development and the like can be greatly assisted; and a powerful platform is provided for kidney toxicity assessment.

The invention belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody combination for detecting cat Cys-C protein and application. The monoclonal antibody combination provided by the invention comprises monoclonal antibodies 4D5 and 3F3, and amino acid sequences of complementary determining regions (CDR) of variable regions of a heavy chain and a light chain of the monoclonal antibodies 4D5 and 3F3 are respectively shown as SEQ ID NO.1 to SEQ ID NO.12. The antibody combination has high specificity and sensitivity, and can effectively recognize cat Cys-C recombinant protein and natural cat Cys-C protein. According to the double-antibody sandwich ELISA detection method constructed based on the antibody combination, positive signals can still be generated under the low concentration of 1ng / mL, no obvious cross reaction exists, and the detection accuracy is remarkably improved. The antibody combination can be used for preparing a detection kit, a test strip, an antibody chip and other tools, and is suitable for cat kidney function evaluation and early auxiliary diagnosis of kidney diseases.

The invention discloses a lupus nephritis marker and application thereof, and belongs to the technical field of biomarkers. The marker for the lupus nephritis, disclosed by the invention, comprises one or more of CD8, CD38 and PD-1. By detecting specific cell surface markers in patient blood, early diagnosis of LN is assisted in a minimally invasive mode, and based on deep comparative analysis of LN patients and healthy people, the specificity and sensitivity of the biomarkers in LN diagnosis are ensured through screening of the biomarkers. In the aspect of differential diagnosis, a clinician is assisted to distinguish LN from other types of kidney diseases, such as membranous nephropathy (MN) and anti-neutrophil cytoplasm antibody related vasculitis (AAV), by analyzing specific biomarker modes of different nephropathy. The dependence on kidney puncture is reduced, related potential risks and inconvenience are avoided, and meanwhile more accurate and timely diagnosis is provided for an SLE patient.

The invention relates to proteins for use in the prevention, treatment or amelioration of kidney diseases or kidney damage, more particularly where the protein is a follistatin-fusion protein.

The present invention provides stem cells enriched with healthy functional mitochondria, pharmaceutical compositions comprising these cells and methods of use thereof for treating renal diseases, disorders and symptoms thereof where the disease may or may not be associated with acquired mitochondrial dysfunction.

To simply provide information showing a degree of a kidney disease of a feline animal.SOLUTION: A urine inspection system includes a storage part and a control part. The storage part stores kidney disease information on a relation between a level of a D-amino acid in urine of a feline animal and a degree of a kidney disease of the feline animal. The control part receives D-amino acid information showing the level of the D-amino acid in the urine from the feline animal from a user terminal belonging to an owner or an inspection institute of the feline animal. Then, the control part estimates the degree of the kidney disease of the feline animal on the basis of the received D-amino acid information and the kidney disease information and transmits kidney disease degree information showing the estimated degree of the kidney disease to the user terminal.SELECTED DRAWING: Figure 4

The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (I), and sub-formulas thereof: Formula (I) or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for treatment or prevention of diseases including heart (e.g. ischemic heart disease, congestive heart failure, and valvular heart disease), lung (e.g., lung inflammation, pneumonia, acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), respiratory (e.g.,respiratory infection, acute respiratory distress syndrome), liver (e.g. acute liver failure and liver fibrosis and cirrhosis), and kidney (e.g. acute kidney injury and chronic kidney disease) disease, inflammatory bowel disease (IBD), ischemic reperfusion injury (e.g., stroke), retinopathy of prematurity (ROP), bronchopulmonary dysplasia (BPD), and white matter injury (WMI).

The invention belongs to the technical field of kidney disease detection, and particularly relates to a renal function dry-type biochemical detection chip and a use method thereof. The chip is combined with a dry biochemical reaction layer through a micro-fluidic technology, and can be used for synchronously detecting renal function markers such as urine creatinine, urea nitrogen and cystatin C. The chip adopts a multi-layer modular lamination design, and sequentially comprises a bottom plate, an electrode layer, a detection layer, a binding layer and a sample adding layer from bottom to top, and each layer is made of a high-molecular polymer with excellent biocompatibility, so that the detection process is not interfered, and the result is accurate and reliable. Sample flow is accurately controlled through the microfluidic channel, multi-index parallel detection is realized, and the detection efficiency is improved. A micro sensor is arranged in the chip, the reaction process is monitored in real time, and data accuracy is ensured. The system has the characteristics of portability and quick response, is suitable for clinical and family self-test, and provides a convenient and efficient solution for renal function monitoring.

In an illustrative embodiment, systems and methods for treating kidney disease in a human patient are disclosed. A method includes advancing a collapsible array of RF electrodes through a urinary tract of the patient in collapsed form and into a position in or near a renal pelvis. The effector is deployed to an expanded form to engage at least a portion of an interior wall of the renal pelvis. RF energy delivered through the array of electrodes target afferent nerves proximate the interior wall of the renal pelvis to inhibit or destroy their function. eGFR of the patient can be raised after treatment according to the method.

To provide a type C natriuretic peptide and a method for treating acute lung injury. [Solution] This disclosure relates to the treatment of lung, liver, and / or kidney disorders by administering therapeutically effective doses of (ultra)long-acting C-type natriuretic peptide (CNP), CNP derivatives, (ultra)long-acting CNP derivatives, or (ultra)long-acting CNP receptor (NPRB) agonists to subjects in need. This disclosure also relates to the treatment of non-cardiovascular causes of hypoxia, elevated inflammatory cell levels in the lungs, pulmonary edema, sepsis, bacteremia, fibrosis in general, and / or interstitial lung disease using these.

The invention discloses application of Htr2b and an inhibitor thereof in prevention or treatment of chronic kidney diseases, provides application of Htr2b as a drug target in screening of drugs for prevention or treatment of chronic kidney diseases, and further provides application of the inhibitor of Htr2b in preparation of drugs for prevention or treatment of chronic kidney diseases. It is found that after the Htr2b function of DIO mice is inhibited, kidney injury caused by high fat is obviously relieved, the Htr2b inhibitor can inhibit important inflammatory factors MCP-1, IL-1, IL-6 and TNF-alpha and ectopic lipid deposition of the chronic kidney diseases, renal function markers of creatinine, urea nitrogen and UACR of the DIO mice can be obviously reduced, and the Htr2b inhibitor has the obvious effect of preventing or treating the chronic kidney diseases and has a good application prospect. The compound can be used for preparing medicines for preventing or treating chronic kidney diseases.

Use of a compound represented by formula (I) or a pharmaceutically acceptable salt thereof or an isotopically labeled compound thereof in the preparation of a drug for preventing or treating neurodegenerative diseases, autoimmune and systemic inflammatory diseases, metabolic and cardiovascular diseases, respiratory diseases, ophthalmic diseases, or kidney diseases.

The present invention provides methods of using non-naturally occurring melanocortin analogs to increase body weight and / or increase food consumption in a subject having a kidney disease and / or a liver disease (e.g., chronic kidney disease, renal failure, non-alcoholic fatty liver disease (NAFLD)). Also provided are methods of stimulating appetite in a subject via administration of a non-naturally occurring melanocortin analogue. The non-naturally occurring melanocortin analogs may be present in pharmaceutical compositions and delivered via parenteral administration (e.g., subcutaneous injection). The methods improve appetite, increase food consumption, increase body weight, muscle mass, and / or fat mass in the subject.

The present invention relates to a benzene-containing polycyclic derivative modulator, a preparation method therefor and the use thereof. In particular, the present invention relates to a compound as shown in general formula (I-1), a preparation method therefor, a pharmaceutical composition containing the compound, and the use thereof as a modulator in the preparation of a drug for treating diabetes, obesity, NASH, renal diseases and diseases associated therewith, wherein each substituent in general formula (I-1) is the same as that defined in the specification.

The invention relates to 1,5-benzothiadiazepine and 1,2,5- benzothiadiazepine derivatives of formula (1). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and / or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases, liver diseases and renal diseases.

The invention relates to a specifically degraded KIM1 liposome, preparation thereof and application of the specifically degraded KIM1 liposome in preparation of medicines for treating kidney diseases, and belongs to the technical field of biological medicines. According to the invention, a KIM1 targeting polypeptide and an E3 ubiquitin ligase ligand (such as lenalidomide) are respectively modified on the surface of a liposome. The lipidosome capable of specifically degrading the KIM1 can be rapidly enriched in a damaged kidney after renal injury occurs, and the KIM1 protein level in the damaged kidney is degraded by 75%. Meanwhile, the druggability problems of poor solubility, low bioavailability and the like caused by large molecular weight of the compound in the PROTAC drug development process are avoided, and the technical problems that drugs are difficult to prepare and kidney injury drugs are lacked in the prior art are solved.

We provide TRPC5 inhibitors for use in treating or reducing the risk of developing kidney disease, diabetic retinopathy, anxiety disorders, depression, or cancer. [Solution] Compounds according to formula (I) or (II), and pharmaceutical compositions containing them are disclosed. A therapeutic method using a compound of formula (I) or (II) to treat, for example, kidney disease is also disclosed. JPEG2026086459000081.jpg3992

The invention discloses lactobacillus mucilaginosus, a microbial agent and application, and belongs to the technical field of microorganisms. The lactobacillus mucus is fermentation lactobacillus mucus and / or lactobacillus reuteri, the fermentation lactobacillus mucus is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.34245, the preservation date is April 17, 2025, and the preservation number is AIML-C0029; the lactobacillus reuteri is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.34601, the preservation date is May 20, 2025, and the lactobacillus reuteri is named as AIML-C0053. The lactobacillus mucilaginosus can be applied to preparation of medicines for treating and / or preventing renal edema and kidney injury, and a new thought is provided for treating or preventing kidney diseases.

The application discloses a traditional Chinese medicine composition for regulating inflammation-oxidative stress-bone metabolism axis and application thereof, and belongs to the field of kidney disease treatment. The traditional Chinese medicine composition is composed of Herba Epimedii, Rhizoma Drynariae, Radix Eucommiae, Radix Rehmanniae Preparata, Radix Angelicae Sinensis, Rhizoma Chuanxiong, Flos Carthami, Radix Salviae Miltiorrhizae, Olibanum, Poria, Rhizoma Atractylodis Macrocephalae, Radix Trichosanthis, Radix Clematidis, Caulis Spatholobi and Radix Glycyrrhizae. The composition can be prepared into pharmaceutically acceptable dosage forms such as granules, granules for oral taking, capsules, tablets, pills, oral liquid or ointments. The traditional Chinese medicine composition has the characteristics of sustained curative effect, good safety and comprehensive regulation of multiple targets, and can be used for preparing drugs for regulating inflammation-oxidative stress-bone metabolism axis, improving mineral and bone metabolism abnormalities of chronic kidney disease and treating chronic musculoskeletal pain of patients with maintenance hemodialysis.

The present disclosure relates to apoptosis-induced stem cells, a method for producing the same, and a pharmaceutical composition for the prevention or treatment of an inflammatory disease or a renal disease, including the same. Cells according to an aspect and a composition including the cells as an active ingredient have an increased IL-10 expression level without including a cryoprotectant, and thus can be effectively used for the prevention or treatment of an inflammatory disease or a renal disease.

The application belongs to the field of biological detection, and particularly relates to a technology and a reagent for detecting NAG by a VRA-NAG substrate method. The linear range of the NAG detection reagent provided by the application can reach (0, 500] U / L; within the range, when the anti-acid is less than or equal to 340 micromoles / L, urea is less than or equal to 42.9 millimoles / L, uric acid is less than or equal to 1.4 millimoles / L, albumin is less than or equal to 100 milligrams / dL, bilirubin is less than or equal to 342 micromoles / L, lactic acid is less than or equal to 6.6 millimoles / L, glucose is less than or equal to 55 millimoles / L, triglyceride is less than or equal to 37 millimoles / L, and oxalic acid is less than or equal to 81 micromoles / L, these components have no obvious interference on the test. Moreover, the relative standard deviation caused by the accelerated aging of the detection reagent for 10 days is not more than ±10%. Compared with the prior art, the kit provided by the application has high sensitivity, wide linear range, strong specificity and good stability, and is conducive to early detection and early treatment of kidney diseases in clinical practice.

The application belongs to the technical field of kidney disease differential diagnosis, and particularly relates to a microbial gene marker for differentiating diabetic nephropathy and membranous nephropathy and application thereof. The application provides sufficient evidence for the differentiation and treatment of clinical diagnosis of diabetic nephropathy and pathological diagnosis of membranous nephropathy based on four microbial markers of Blautia, Akkermansia, Sphingomonas and Granulicatella.